How much does one shot of Lenacapavir cost?

Lenapavir sodium/salanca (Lenacapavir) is a new long-acting HIV-1 capsid inhibitor. It acts on the capsid protein of the HIV virus and interferes with multiple key steps of viral replication, thereby inhibiting the spread of the virus in the body. Different from traditional antiretroviral drugs, the biggest innovation of lenapavir sodium lies in the dosage form and administration method. Tablets and long-acting injections have been developed. In particular, injections can be administered once every 6 months, which greatly reduces patients' compliance problems with daily or weekly medication.

In clinical application, lenapavir sodium is mainly used forHIV-1 infection (AIDS) patients, especially those who have developed drug resistance or failed treatment in previous antiviral treatments. Due to its unique mechanism of action, lenapavir sodium can be used in combination with other antiretroviral drugs to form new treatment combinations and improve the overall efficacy. This combined strategy not only improved virological suppression rates but also showed potential advantages in reducing the emergence of drug resistance. Therefore, it has important breakthrough significance in the field of HIV treatment.

In terms of price, lenapavir sodium is currently on the market in the United States and Europe. The United StatesFDA will approve its marketing in December 2022. The specification of overseas injections is 463.5mg/1.5ml*2, and the price of a box is about 100,000 yuan. Due to its short time on the market, it is currently difficult to be widely purchased in China, and it has not yet been included in the scope of medical insurance reimbursement. There are no relevant generic drugs on the market, making it difficult to reduce prices in the short term, which is an economic burden for some patients. Although tablets and injections have been approved in China, supply channels and selling prices still need to be further clarified.

In general, lenapavir sodium provides a new treatment option for HIV-infected patients with its advantage of long-acting injection, especially suitable for people with poor compliance or high risk of drug resistance in traditional therapies.

Reference materials:https://www.drugs.com/sunlenca.html